Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.

@article{Gaspari1998PharmacokineticsAR,
  title={Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.},
  author={Flavio Gaspari and M F Anedda and O Signorini and Susana Amuchastegui and Norberto Perico and Giuseppe Remuzzi},
  journal={Transplantation proceedings},
  year={1998},
  volume={30 5},
  pages={
          1654-5
        }
}
ALMOST two decades of extensive research and clinical experience with cyclosporine (CyA) immunosuppression have significantly contributed to the reduced incidence of acute allograft rejection and improved short-term transplant survival rates and overall clinical outcome. Recently, a new formulation of CyA, Neoral, has become available. It could theoretically overcome the problems of inter and intrapatient biopharmaceutic and pharmacokinetic variability that accompany the conventional Sandimmune… 
1 Citations
Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs.
TLDR
It is concluded that the degradation of soybean oil emulsion was needed for SG to be absorbed through the intestine, suggesting that absorption of the dosage formulation should be paid attention when poorly water-soluble drugs are orally administered with lipid-based formulation.

References

SHOWING 1-10 OF 10 REFERENCES
Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
TLDR
The steady-state pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine (Sandimmune Neoral) were compared with Sandimmune in 18 clinically stable renal allograft recipients and showed less variability and yielded a stronger correlation between trough concentration and systemic exposure (AUC) compared withSandimmune.
Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection.
TLDR
It is suggested that variable oral bioavailability of CsA represents a biopharmaceutical risk factor for the occurrence of chronic rejection.
A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
TLDR
MeCsA appears to be a safe and effective therapy in stable renal transplant patients and provides superior and more consistent absorption of cyclosporine when compared with ConCsA, a prospective, randomized, concentration-controlled, pharmacoepidemiologic study.
Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation.
TLDR
It is speculated that an excessive renal synthesis of endothelin is the cause of the daily renal hypoperfusion observed in patients with renal transplants given cyclosporine.
Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.
TLDR
Although the clinical utility of this reproducible pharmacokinetic behavior remains to be demonstrated in the de novo transplant setting, the markedly reduced intraindividual variation produced by administration of CsA-ME will likely improve the accuracy of pretransplant prediction of, and reduce the frequency of subsequent adjustments in,CsA doses.
Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration.
Accurate monitoring of cyclosporine (CsA) dosage is still a problem, because measurement of the area under the curve (AUC)--the most appropriate indicator of exposure to CsA--requires a number of
The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
TLDR
The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation sandimmun-neoral to help improve the quality of life for transplant patients.